# Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS

> **NCT04536350** · PHASE2 · TERMINATED · sponsor: **Prof. Dr. Jörg Leuppi** · enrollment: 83 (actual)

## Conditions studied

- Covid19
- Corona Virus Infection
- ARDS
- Aviptadil

## Interventions

- **DRUG:** Aviptadil 67μg
- **DRUG:** Placebo 0.9% NaCl solution

## Key facts

- **NCT ID:** NCT04536350
- **Lead sponsor:** Prof. Dr. Jörg Leuppi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-18
- **Primary completion:** 2023-06-14
- **Final completion:** 2023-06-14
- **Target enrollment:** 83 (ACTUAL)
- **Why stopped:** Difficulties recruiting participants for the Aviptadil study as there are nowadays very few hospitalized COVID patients. Continuous screening has been carried out but none of the patients met the eligibility criteria for the study.
- **Last updated:** 2024-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04536350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04536350, "Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04536350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*